What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?

Davies, Rhian Siân

What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer? [electronic resource] - Anticancer research Oct 2015 - 5615-21 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1791-7530


Aged
Aged, 80 and over
Androgen Antagonists--therapeutic use
Androstenes--therapeutic use
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prostatic Neoplasms, Castration-Resistant--drug therapy
Retrospective Studies
Survival Rate